Valuation: MannKind Corporation

Market Cap 124.88Cr 108.56Cr 101.05Cr 93Cr 175.19Cr 12TCr 177.91Cr 1.19TCr 467.46Cr 5.93TCr 469.01Cr 458.7Cr 20TCr P/E 2026 *
-456x
P/E 2027 * 25.6x
Enterprise Value 124.88Cr 108.56Cr 101.05Cr 93Cr 175.19Cr 12TCr 177.91Cr 1.19TCr 467.46Cr 5.93TCr 469.01Cr 458.7Cr 20TCr EV / Sales 2026 *
2.7x
EV / Sales 2027 * 2.39x
Free-Float
98.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: MannKind Corporation

1 day-4.87%
1 week-5.33%
1 month-8.22%
3 months+38.16%
6 months-32.35%
Current year-31.04%
1 week 3.82
Extreme 3.82
4.24
1 month 3.71
Extreme 3.7101
4.55
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap.
17/07/26 Sell

General Counsel

-24,109 0.0078%
17/07/26 Sell

Director

-52,485 0.0170%
15/07/26 Fiscal year

Chief Executive Officer

10,63,720 0.3443%
Change 5-day change 1-year change 3-year change Capi.($)
-4.87%-5.33%+3.44%-14.44% 124.88Cr
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average -0.60%-3.95%+31.37%+140.17% 2.35TCr
Weighted average by Cap. +0.20%-2.97%+28.54%+119.27%

Financials

2026 *2027 *
Net sales 46Cr 40Cr 37Cr 34Cr 65Cr 4.41TCr 66Cr 441.1Cr 173.12Cr 2.2TCr 173.69Cr 169.87Cr 7.37TCr 52Cr 45Cr 42Cr 39Cr 73Cr 4.99TCr 74Cr 498.18Cr 195.52Cr 2.48TCr 196.17Cr 191.86Cr 8.32TCr
Net income 40.29L 35.03L 32.6L 29.93L 56.52L 38Cr 57.4L 3.84Cr 1.51Cr 19Cr 1.51Cr 1.48Cr 64Cr 5.57Cr 4.84Cr 4.51Cr 4.14Cr 7.81Cr 531.78Cr 7.94Cr 53Cr 21Cr 264.74Cr 21Cr 20Cr 887.72Cr
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
31/26/31 $3.910 -4.87% 54,04,120
30/26/30 $4.110 +6.75% 41,40,742
29/26/29 $3.850 -1.53% 35,87,211
28/26/28 $3.910 -1.01% 36,57,168
27/26/27 $3.950 -4.36% 53,25,676
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.910USD
Average target price
7.719USD
Spread / Average Target
+97.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNKD Stock